Daniela Vilasboas-Campos

  • C. elegans
  • Neurodegenerative disorders
  • drug screening
  • natural compounds
  • antioxidants
  • protein agregation
  • Machado-Joseph disease
  • proteostasis
  • Therapy

Daniela Vilasboas-Campos obtained a M.Sc. in Plant Molecular Biology, Biotechnology and Bioentrepreneurship (2018) at the University of Minho. She has developed her master’s thesis work at the Life and Health Sciences Research Institute (ICVS) dedicated to the evaluation of antioxidant and neuroprotective effects of medicinal plant extracts in C. elegans models of tauopathy and polyglutamine disease. In 2018, she integrated the EXOS3 collaborative research project with the aim of identifying novel disease-modifying genes and pathways of MJD/SCA3 patients, using a whole-exome approach. Daniela Vilasboas-Campos is currently an PhD student in Health Sciences, integrated in the Translational Neurogenetics research team, at ICVS, School of Medicine at the University of Minho. In 2019, she was awarded an individual PhD fellowship financed by the Portuguese Foundation for Science and Technology (FCT) with a project focusing on chemogenomics screening for novel therapeutic target identification in a C. elegans model of MJD/SCA3. The lack of effective therapeutic strategies for MJD/SCA3 motivates her to perform large-scale phenotype-based drug and genetic screenings in C. elegans, aiming at identifying novel molecules and therapeutic targets. Therefore, she established an automated assay to screen for molecules able to act as enhancers of protein-folding and homeostasis capacity. Currently, she is dedicated to testing several therapeutic approaches in collaborations with various pharmaceutical companies, screening libraries of novel and repurposed compounds and identifying genetic modifier pathways that can provide targets for new drug development, offering new therapeutic possibilities for MJD/SCA3 patients. Vilasboas-Campos has published 5 scientific articles to date (two as first-author and three as co-author) in international peer-reviewed journals.

Scientific Highlights

Vilasboas-Campos, D., Costa, M. D., Teixeira-Castro, A., Rios, R., Silva, F. G., Bessa, C., Dias, A. C. P., & Maciel, P. (2021). Neurotherapeutic effect of Hyptis spp. leaf extracts in Caenorhabditis elegans models of tauopathy and polyglutamine disease: Role of the glutathione redox cycle. Free Radical Biology & Medicine, 162, 202–215. https://doi.org/10.1016/j.freeradbiomed.2020.10.018

Vilasboas-Campos, D., Costa, M. D., Teixeira-Castro, A., Rios, R., Silva, F. G., Aierken, A., Zhang, X., Bessa, C., Dias, A. C. P., & Maciel, P. (2020). Data on the effects of Hyptis spp. and Lycium spp. plant extracts in C. elegans models of genetically determined neurodegenerative diseases. Data in brief, 33, 106598. https://doi.org/10.1016/j.dib.2020.106598

Raposo, M., Bettencourt, C., Melo, A. R. V., Ferreira, A. F., Alonso, I., Silva, P., Vasconcelos, J., Kay, T., Saraiva-Pereira, M. L., Costa, M. D., Vilasboas-Campos, D., Bettencourt, B. F., Bruges-Armas, J., Houlden, H., Heutink, P., Jardim, L. B., Sequeiros, J., Maciel, P., & Lima, M. (2022). Novel Machado-Joseph disease-modifying genes and pathways identified by whole-exome sequencing. Neurobiology of disease, 162, 105578. https://doi.org/10.1016/j.nbd.2021.105578

Jalles, A.*, Vieira, C.*, Pereira-Sousa, J., Vilasboas-Campos, D., Mota, A. F., Vasconcelos, S., Ferreira-Lomba, B., Costa, M. D., Da Silva, J. D., Maciel, P., & Teixeira-Castro, A. (2022). Aripiprazole Offsets Mutant ATXN3-Induced Motor Dysfunction by Targeting Dopamine D2 and Serotonin 1A and 2A Receptors in C. elegans. Biomedicines, 10(2), 370. https://doi.org/10.3390/biomedicines10020370

Pereira-Sousa, J., Ferreira-Lomba, B., Bellver-Sanchis, A., Vilasboas-Campos, D., Fernandes, J. H., Costa, M. D., Varney, M. A., Newman-Tancredi, A., Maciel, P., & Teixeira-Castro, A. (2021). Identification of the 5-HT1A serotonin receptor as a novel therapeutic target in a C. elegans model of Machado-Joseph disease. Neurobiology of disease, 152, 105278. https://doi.org/10.1016/j.nbd.2021.105278


Serotonin signaling and proteostasis

This project addresses an unmet medical need- the lack of effective treatment for any of the aging-associated neurodegenerative diseases. Due to the worldwide aging of the population, by 2050 it is expected that over 135 million people…

Read More